Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026)

Prelude Therapeutics' Current Deferred Revenue history spans 3 years, with the latest figure at $31.0 million for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $31.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $31.0 million, a N/A change, with the full-year FY2025 number at $33.7 million, changed N/A from a year prior.
  • Current Deferred Revenue hit $31.0 million in Q1 2026 for Prelude Therapeutics, down from $33.7 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PRLD hit a ceiling of $33.7 million in Q4 2025 and a floor of $3.0 million in Q2 2024.
  • Historically, Current Deferred Revenue has averaged $22.6 million across 3 years, with a median of $31.0 million in 2026.